Investors – Calliditas Therapeutics AB

Press releases

Jan 21, 2021Calliditas Announces Full Enrollment of the Phase 3 NefIgArd Trial
Jan 20, 2021Calliditas announces clinical development plan for setanaxib and comments on data from Part A of NefIgArd study at today´s R&D Day
Jan 18, 2021Positive Phase 1 results in high-dose setanaxib trial

All press releases

Share price Sweden

Share price US

Interim Report Q3 2020

On November 12, 2020, at 07:00 CET, Calliditas Therapeutics published its interim report for the third quarter 2020.

Read the report

Calendar

Feb 18, 2021Year-end report for the period January 1 – December 31, 2020
Apr 27, 2021Annual Report 2020
May 13, 2021Interim report for the period January 1 – March 31, 2021